Proassurance | 8-K: FY2025 Q3 Revenue: USD 279.55 M

LB filings
2025.11.04 21:39
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 279.55 M.

EPS: As of FY2025 Q3, the actual value is USD 0.03, missing the estimate of USD 0.27.

Specialty Property and Casualty Segment

  • Net Premiums Written: $205.6 million for Q3 2025, a decrease of 7.2% compared to Q3 2024. For the nine months ended September 30, 2025, net premiums written were $562.2 million, down 4.6% from the same period in 2024.
  • Net Premiums Earned: $180.8 million for Q3 2025, a decrease of 4.2% compared to Q3 2024. For the nine months ended September 30, 2025, net premiums earned were $543.4 million, down 3.3% from the same period in 2024.
  • Combined Ratio: 109.1% for Q3 2025, compared to 100.0% for Q3 2024. For the nine months ended September 30, 2025, the combined ratio was 104.5%, compared to 105.3% for the same period in 2024.

Workers’ Compensation Insurance Segment

  • Net Premiums Written: $43.4 million for Q3 2025, a decrease of 6.3% compared to Q3 2024. For the nine months ended September 30, 2025, net premiums written were $136.4 million, down 0.2% from the same period in 2024.
  • Net Premiums Earned: $41.0 million for Q3 2025, a decrease of 2.0% compared to Q3 2024. For the nine months ended September 30, 2025, net premiums earned were $124.0 million, down 0.5% from the same period in 2024.
  • Combined Ratio: 113.5% for Q3 2025, compared to 111.4% for Q3 2024. For the nine months ended September 30, 2025, the combined ratio was 113.0%, compared to 112.3% for the same period in 2024.

Segregated Portfolio Cell Reinsurance Segment

  • Net Premiums Written: $12.3 million for Q3 2025, an increase of 5.0% compared to Q3 2024. For the nine months ended September 30, 2025, net premiums written were $34.5 million, down 12.2% from the same period in 2024.
  • Net Premiums Earned: $11.6 million for Q3 2025, a decrease of 7.8% compared to Q3 2024. For the nine months ended September 30, 2025, net premiums earned were $34.7 million, down 14.0% from the same period in 2024.
  • Combined Ratio: 88.3% for Q3 2025, compared to 94.6% for Q3 2024. For the nine months ended September 30, 2025, the combined ratio was 89.3%, compared to 100.6% for the same period in 2024.

Corporate Segment

  • Net Investment Income: $39.3 million for Q3 2025, an increase of 8.5% compared to Q3 2024. For the nine months ended September 30, 2025, net investment income was $113.5 million, up 8.1% from the same period in 2024.

Outlook / Guidance

ProAssurance anticipates closing the transaction with The Doctors Company by June 30, 2026, subject to regulatory approvals. The Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and ProAssurance shareholders have overwhelmingly approved the transaction.

Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer